Delhi government hikes nursing interns' stipend from Rs 500 to 13,150
The decision, taken in a cabinet meeting, will benefit nearly 180 nursing interns from the three nursing colleges attached to the Delhi government's Guru Teg Bahadur Hospital, Lok Nayak Hospital, and Deen Dayal Upadhyay Hospital, a health department official told PTI.
Health Minister Pankaj Singh said the revision addresses a long-pending demand of nursing students and aims to provide them parity with MBBS interns.
"For 27 years, this issue was ignored. By raising the stipend to Rs 13,150, we are ensuring that nursing interns receive the dignity, respect and support they deserve," he said.
He also said that the government expects the hike to improve the morale of students, provide them the financial stability during their training, and strengthen the city's healthcare workforce.
Live Events
A government note said, "Earlier governments ignored this issue for nearly three decades, but under the guidance of Prime Minister Narendra Modi and the leadership of Chief Minister Rekha Gupta, our government has resolved this disparity."
It added, "With this increased stipend, we are ensuring respect and dignity for nursing interns."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
United News of India
21 minutes ago
- United News of India
Inclusive approach needed to tackle rare diseases: Pharma Secretary
New Delhi, Aug 21 (UNI) Addressing the growing significance of rare diseases, a matter often overlooked historically, Amit Agrawal, Secretary of Department of Pharmaceuticals in the Ministry of Chemicals & Fertilizers, stressed the need for a comprehensive and inclusive approach to combat these disorders. He pointed out that while rare diseases may seem infrequent on an individual basis, collectively they impact nearly one in every twenty persons, approximately 5 per cent of the population, making it a critical public health challenge. Agrawal made these remarks during the inaugural session of the Rare Diseases Conference 2025, organized by FICCI, which was themed 'Making Rare Care Possible: Availability, Accessibility, Awareness.' The Secretary urged the issue be viewed not only as a medical or technical concern but through a human lens of inclusion and empathy. Citing Prime Minister Narendra Modi's inclusive vision for Divyangjan, he called upon the government, industry, academia, and civil society to unite in addressing the multifaceted burdens borne by patients and their caregivers. Referring to the Prime Minister's recent Independence Day address, he recalled: 'We are known as the pharmacy of the world, but isn't it the need of the hour to invest in research and development? Shouldn't we be the ones providing the best and most affordable medicines for the welfare of humanity?' The Secretary further informed that rare diseases have been incorporated as a focus area under the Production Linked Incentive (PLI) Scheme for Pharmaceuticals. This initiative has supported the development of eight drugs targeting rare conditions, including Eliglustat for Gaucher's Disease, where treatment costs have been drastically reduced from Rs 1.8–3.6 crore annually to Rs 3–6 lakh. Other supported treatments include Trientine for Wilson's Disease, Nitisinone for Tyrosinemia Type 1, and Cannabidiol for Lennox–Gastaut Syndrome. He underscored that these significant cost reductions exemplify the transformative potential of targeted policy measures, Agrawal said. In addition, the Secretary encouraged corporate entities to integrate rare disease patients into their CSR initiatives and patient assistance programmes, given the considerable financial and emotional hardships faced by affected families. UNI AJ AAB
Business Standard
an hour ago
- Business Standard
Fortis Healthcare partners with Ekana Group to manage 550-bed super specialty hospital in Lucknow
Fortis Healthcare informed that it has signed a collaboration agreement with the Ekana Group for operations and management of a 550-bed greenfield super specialty hospital in Lucknow. The upcoming hospital will be constructed by the Ekana Group near Gomti Nagar in the state capital of Uttar Pradesh. Under the agreement, Fortis Healthcare will oversee operations and management once the facility is ready. The planned hospital is expected to function as a Centre of Excellence for tertiary care services, offering advanced medical infrastructure and global best practices to patients in Lucknow and beyond. Dr Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare said, "We are delighted to partner with Ekana Group to bring a state-of-the-art tertiary healthcare facility to the heart of Lucknow. Once operational, this new 550-bed super-specialty hospital near Gomti Nagar will significantly enhance access to advanced medical care for the city and its surrounding regions. This collaboration marks Fortis Healthcares third major presence in Uttar Pradesh, joining our network hospitals in Noida and Greater Noida, and underscores our steadfast commitment to expanding high-quality healthcare across the state. Uday Sinha, Promoter of Ekana Group, said, We are happy to join hands with one of the leading healthcare chains in India - Fortis Healthcare to develop a leading-edge tertiary care hospital, one that will significantly enhance access to advanced medical services and deliver patient care where its most needed. Fortis Healthcare is a leading integrated healthcare delivery service provider in India. Its verticals include hospitals, diagnostics, and day care specialty facilities. As of now, the company operates 33 healthcare facilities (including JVs and O&M facilities) across 11 states, with a network of over 5,700 operational beds and 400 diagnostics labs. The company reported a 56.83% surge in consolidated net profit to Rs 260.28 crore in Q1 FY26, compared to Rs 165.96 crore in Q1 FY25. Revenue from operations rose 16.55% year-on-year (YoY) to Rs 2,166.72 crore in the quarter ended 30 June 2025. Shares of Fortis Healthcare shed 1.03% to Rs 953.65 on the BSE.
News18
3 hours ago
- News18
Sakhiya Skin Clinic files draft papers with BSEs SME to raise funds via IPO
Agency: New Delhi, Aug 21 (PTI) Sakhiya Skin Clinic on Thursday said it has filed preliminary papers with BSE's SME platform to raise funds through an Initial Public Offering (IPO). The IPO is a mix of fresh issuance of up to 50.10 lakh equity shares and an offer for sale of up to 11.62 lakh shares by promoters, Jagdishkumar Jadavbhai Sakhiya and Rupalben Jagdishbhai Sakhiya, the company said in a statement. The proceeds from the fresh issue to the tune of Rs 42.57 crore will be used to open new clinics across India, funds worth Rs 9.65 crore will be used for investment in its subsidiary, Dr Sakhiya's Advanced Skin Science LLP, and Rs 3.2 crore for repayment of debt. The company will also use funds worth Rs 88.5 lakhs for upgrading the technology & facilities, and the balance for general corporate purposes. Incorporated in 2011, Sakhiya Skin Clinic is a dermatology-focused healthcare services provider in India. Surat-based company specialises in dermatology, cosmetology, and aesthetic treatments, along with its own cosmeceutical product line. It reported a revenue of Rs 52.87 crore from its healthcare services and a profit after tax of Rs 10.92 crore in FY25. The company has served over 5.40 lakh patients through its network of 35 clinics across 24 cities, primarily operating in Gujarat and Maharashtra. The equity shares are proposed to be listed on the BSE's SME. GYR Capital Advisors is the sole book running lead manager for the IPO. PTI HG DR DR view comments First Published: August 21, 2025, 14:00 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy. Loading comments...
